{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"52"}],"units":"Participants"}],"description":"MRD\\[-\\] response was defined as achievement of MRD\\[-\\] status using next generation sequencing (NGS) based method in the bone marrow at any time.","groups":[{"description":"Carfilzomib was administered intravenously on days 1, 8, and 15 (± 2 days) of each 28-day cycle for up to 12 cycles or progression or end of study. A dose of 20 mg/m\\^2 was administered on day 1 of cycle 1; all subsequent doses were 56 mg/m\\^2. From cycle 13, the frequency of carfilzomib administration was reduced to days 1 and 15 (± 2 days) per cycle until progression or end of study.\n\nDexamethasone was administered orally or intravenously at a dose of 40 mg on days 1, 8, 15, and 22 of each cycle during cycles 1 to 12, and at a dose of 20 mg on days 1 and 15 from cycle 13 until progression or end of study.\n\nPomalidomide 4 mg was administered orally on days 1 to 21 of each cycle until progression or end of study.","id":"OG000","title":"Carfilzomib With Pomalidomide and Dexamethasone (KPd)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The safety analysis set included all participants who received at least 1 dose of carfilzomib.","reportingStatus":"POSTED","timeFrame":"From day 1 cycle 1 until the end of study (EOS); the mean duration of KPd treatment as of the EOS was 55.3 weeks","title":"Number of Participants Achieving MRD[-] Response","type":"SECONDARY","unitOfMeasure":"Participants"}